Arch Therapeutics Appoints Senior Management Team Members

Arch Therapeutics Appoints Senior Management Team Members 
CAMBRIDGE, MA -- (Marketwired) -- 07/08/13 --  Arch Therapeutics,
Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company
and developer of AC5(TM), a novel product aimed at controlling
bleeding and fluid loss in order to provide faster and safer surgical
and interventional care, is pleased to appoint Mr. Alan Barber as CFO
and Mr. William M. Cotter as COO. 
Mr. Barber was appointed as the Chief Financial Officer of the
Company effective June 26, 2013, and has served as the Chief
Financial Officer of Arch Biosurgery, Inc. ("ABS") since August 2008.
He has over 30 years of financial management experience. Since
September 2005, he has been and continues to be an independent
consultant on financial matters. Prior to that, Mr. Barber was the
Chief Financial Officer for a number of technology and life science
start-up companies including Biotrove, Inc. from April 2004 to
September 2005, Omnisonics Medical Technologies, Inc. from October
2001 to April 2004, Innovation Chain, Inc. from October 2000 to
September 2001, from December 1999 to October 2000, Medical
Foods, Inc. from November 1997 to October 1999 and Ergo Science, Inc.
from October 1993 to November 1997. Previously, Mr. Barber was a
Partner with the international accounting firm of
PricewaterhouseCoopers (formerly Coopers & Lybrand) from July 1979 to
October 1993, where he was elected as a Partner in the firm in July
1986. Prior to that, he worked for the international accounting firm
KPMG from May 1975 to July 1979. Mr. Barber received a Bachelor of
Science degree in Accounting from the Florida State University,
Rovetta School of Business, and is a Certified Public Accountant. 
Mr. Cotter has been appointed as Chief Operating Officer effective
July 8, 2013 and has been advising ABS since 2011. He is an industry
veteran who brings expertise in operations and product development in
his role to Arch Therapeutics. Mr. Cotter has over 30 years of
operational experience in Medical Devices, Diagnostics, Biologics and
Life Science companies, ranging from early stage startups to large
multinational corporations. Mr. Cotter has served in senior
operations and development roles for companies including Cohera
Medical, Helicos Biosciences, Closure Medical Corporation (Johnson &
Johnson), Sanofi Diagnostics Pasteur (Beckman Coulter), Genetic
Systems Corporation (Bio-Rad) and Advanced Technology Laboratories
(Phillips HealthCare). Mr. Cotter spent 10 years as VP Operations of
Closure Medical Corporation where he was part of the team that
developed Dermabond(R), the world's first synthetic topical skin
adhesive approved by the FDA. He had direct responsibility and
accountability for all product transfers from R&D, Engineering,
Quality Control, Document Control, Production and Logistics. He was
the development project leader and co-inventor of the Dermabond TSA
ProPen delivery applicator, which won the 2004 Medical Design
Excellence Gold Medal Award. He was an integral part of the Closure
Medical senior management team that led to a successful acquisition
by Johnson & Johnson. Prior to Closure Medical, he spent 8 years with
Sanofi Diagnostics Pastuer, where he had direct responsibility for
all North American industrial sites and chaired the World Wide
Manufacturing Committee for this International In-Vitro Diagnostics
Company. Mr. Cotter is listed as co-inventor on 8 US patents and is a
graduate of Ohio University. 
Company CEO, Dr. Terrence Norchi comments, "We are delighted to
announce the appointments of both Alan and Bill. Their expertise,
commitment and overall level of professionalism have been a hallmark
of my previous experiences with them both. As our Company moves into
this next phase of development, it is reassuring to know that we have
capable hands managing our various obligations and future
Additional details regarding Arch Therapeutics, Inc. and its
agreements are filed as part of the Company's continuous public
disclosure as a reporting issuer under the Securities Exchange Act of
1934 filed with the Securities and Exchange Commission ("SEC"), and
are available at the SEC's website at For more
information, visit our website at 
About Arch Therapeutics, Inc. (OTCQB: ARTH)
 Arch Therapeutics, Inc.
(OTCQB: ARTH) is a medical device company developing a novel approach
to stop bleeding (hemostasis) and control leaking (sealant) during
surgery and trauma care. Arch's goal is to develop and commercialize
products based on our innovative technology platform that make
surgery and interventional care faster and safer for patients. Arch's
flagship development stage product candidate known as AC5(TM) is
being designed to elegantly achieve hemostasis in minimally invasive
and open surgical procedures. Find out more at  
Notice Regarding Forward-Looking Statements
 This news release
contains "forward-looking statements" as that term is defined in
Section 27(a) of the Securities Act of 1933, as amended, and Section
21(e) of the Securities Exchange Act of 1934, as amended. Statements
in this press release that are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future. Such
forward-looking statements include, among other things, references to
novel technologies and methods, our business and product development
plans and projections, or market information. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or technologies
and operating as a development stage company, our ability to retain
important members of our management team and attract other qualified
personnel, our ability to raise the additional funding we will need
to continue to pursue our business and product development plans, our
ability to develop and commercialize products based on our technology
platform, and market conditions. These forward-looking statements are
made as of the date of this news release, and we assume no obligation
to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the
forward-looking statements. Although we believe that any beliefs,
plans, expectations and intentions contained in this press release
are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate.
Investors should consult all of the information set forth herein and
should also refer to the risk factors disclosure outlined in the
reports and other documents we file with the SEC, available at 
On Behalf of the Board, 
Terrence W. Norchi, MD.
 Arch Therapeutics, Inc. 
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Press spacebar to pause and continue. Press esc to stop.